Caris Life Sciences, a molecular science company, and Ono Pharmaceutical Co., Ltd., a pharmaceutical company, entered a strategic collaboration to leverage Caris’ molecular profiling, including its novel, liquid biopsy circulating nucleic acids sequencing (cNAS) assay, across several studies.   Under the agreement, Caris will provide comprehensive molecular profiling analysis in support of several Ono clinical studies evaluating a range of targeted and immune-based therapies, including a...